MHU 650
Alternative Names: MHU-650; NOV 16Latest Information Update: 25 Jul 2024
At a glance
- Originator MorphoSys; Novartis Pharmaceuticals
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Diabetic macular oedema; Retinal oedema; Retinal vein occlusion
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (Intravitreous, Injection)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Diabetic-macular-oedema in USA (Intravitreous, Injection)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Retinal oedema in USA (Intravitreous, Injection)